EP1421993A1 - Vorrichtung zur Separierung und Ausgabe von Plasma - Google Patents
Vorrichtung zur Separierung und Ausgabe von Plasma Download PDFInfo
- Publication number
- EP1421993A1 EP1421993A1 EP03025228A EP03025228A EP1421993A1 EP 1421993 A1 EP1421993 A1 EP 1421993A1 EP 03025228 A EP03025228 A EP 03025228A EP 03025228 A EP03025228 A EP 03025228A EP 1421993 A1 EP1421993 A1 EP 1421993A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- separating element
- plasma
- area
- blood
- separating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000926 separation method Methods 0.000 claims abstract description 64
- 210000004369 blood Anatomy 0.000 claims abstract description 45
- 239000008280 blood Substances 0.000 claims abstract description 45
- 239000012503 blood component Substances 0.000 claims abstract description 24
- 238000012360 testing method Methods 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 40
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 17
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 16
- 239000012491 analyte Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 10
- 230000000717 retained effect Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 4
- 238000002716 delivery method Methods 0.000 claims 1
- 239000003365 glass fiber Substances 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 6
- 210000002381 plasma Anatomy 0.000 description 137
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 239000008139 complexing agent Substances 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000009534 blood test Methods 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0825—Test strips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0481—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure squeezing of channels or chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/52—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2575—Volumetric liquid transfer
Definitions
- the invention relates to the field of plasma extraction, particularly at analytical method for determining a concentration of blood components matters.
- blood tests cannot be performed with whole blood because it contains corpuscular components (blood cells) that would have disruptive influences on the execution of the method. It is therefore necessary to carry out many analytical procedures, first the plasma from the To obtain whole blood, which should be free of cellular material if possible.
- a common method for obtaining plasma for blood tests is the centrifugation process, in which, due to centrifugal forces, cellular components of the Blood are separated.
- This process is complex and is particularly suitable not if only small amounts of plasma are needed for an analysis.
- plasma quantities can only be used in the range of a few microliters.
- carrier-bound tests in which the smallest possible and most compact Analysis system, for example in the form of a test strip, is present.
- the sample liquid is in Brought into contact with such an analysis element.
- test element Reagent reacts with the analyte to be determined within a short period of time, so that a physically detectable change to the analysis element he follows.
- a change can be, for example, a color change or a Change of an electrical measured variable.
- this is Measure and calculate change so that an analytical result is output can be.
- HDL test High Density Lipoproteins
- the manifestation of a coronary heart disease is based on some known parameters, such as B. to recognize the total cholesterol in the blood, plasma or serum.
- LDL Low Density Lipoproteins
- HDL high density
- the HDL cholesterol is determined, for example, using an analysis element, as is known in the prior art (e.g. HDL test elements from the company Roche Diagnostics GmbH). Since this is a separate determination of HDL cholesterol the other existing lipoprotein classes must be different from the rest Blood components are separated so that the determination of HDL cholesterol done from plasma. Such a test requires, for example, a plasma volume of about 40 ⁇ l, so that a concentration determination regardless of the given Plasma volume can be carried out. For the determination of HDL cholesterol only pure plasma can be used in which there are largely no blood components are included. The determination of the HDL concentration continues a complexing agent is used, which is also integrated in the test element. The Plasma is now applied to the area of the test element in which the complexing agent is is available. For the analysis of HDL cholesterol z. B. in the state of Technology of complexing agents EDTA used.
- an analyte can also be determined from pure plasma using a Test element take place in which no complexing agent for determining an analyte necessary is.
- test elements are used, for example, for enzyme determination used and are in the prior art, inter alia, in document DE 3130749 described.
- Test elements that determine an analyte from pure plasma however contain no complexing agent, are often designed so that a plasma separation can be achieved by the test element itself. For this include such Test elements in addition to a reagent layer a separation layer. For measurement Whole blood is first applied to the separation layer. Blood components are separated from plasma within the separation layer, whereby the plasma is passed on to the reagent layer.
- an analyte can thus be made from pure plasma even though blood is applied to the test element has been.
- a plasma separation layer integrated in the test element can not be used when using complexing agents.
- Has to be Complexing agents are used to determine an analyte, it turns out that a separation of the plasma from blood is prevented by the complexing agent in the test element becomes. A plasma separation can then no longer be carried out by the test element be performed if the test element contains a complexing agent.
- HDL cholesterol is only one important example of one Analyte determination, which require small amounts of pure plasma for analysis. Further Areas of application for the use of released plasma are shown in Area of clinical analysis. Because currently preferred in diagnostic practice Test strips are used as analysis systems, the need for simple procedures increases to be able to use small amounts of plasma, so that overall this results in a simplification as well as a quick flow of the analysis procedures.
- the plasma extraction methods mentioned also have the disadvantage that a high There is a risk of the fine pores being closed mechanically or by addition of cellular material clogging the pore walls. This will reduce the filter capacity limited. However, increasing the filter capacity would make it larger Require space requirement of the filter medium. This in turn would relate to that adversely affect the sample volume applied and the plasma volume obtained.
- a filtering process for plasma extraction is described in US Pat. No. 4,477,575 with a glass fiber layer, through which the relation between sample volume and obtained plasma volume is improved.
- the volume of the plasma to be separated is preferably less than 30% of the suction volume of the glass fiber layer.
- a vessel for plasma collection is based on a similar principle Patent application EP 0 785 012 is described. This is also a pressure on Filter material exerted on which blood was previously applied, so that a plasma separation takes place. As already described above, this is also due to the Squeezing a destruction of the blood cells, so that no pure plasma extraction takes place. The plasma is only destroyed by the destruction of the blood cells Once contaminated, it is not suitable for use in a variety of analysis tests suitable.
- the object of the invention is to provide an apparatus and a method which to obtain the purest possible plasma on a microliter scale from whole blood suitable is.
- the disadvantages of the prior art described should be overcome become.
- the invention includes a device for separating and dispensing plasma.
- the device comprises a separating element, which includes a first region who is given a blood test. In the first area of the separating element there are corpuscular ones Blood components essentially completely retained, while advantageously by capillary forces of the separating element plasma in a second area of the Separating element is directed.
- the separating element is arranged in the device that the first area of the separating element for the user to supply blood is accessible.
- the device includes an output unit, which according to the Plasma separation acts on the second area of the separating element without the first area of the separating element is exposed to a z. B. to one Hemolysis of the blood would result. Does the output unit only affect the second area of the separating element, the separated plasma from the second Area released and dispensed through an outlet of the device.
- the invention further includes a system for the detection of analytes in the blood.
- the system includes - as described -
- a test element that separated by the device when abandoned Plasmas enables the detection of an analyte in the plasma.
- the device according to the invention ensures effective plasma extraction in the Microliter scale already from small sample volumes. For example plasma volumes of 30 ⁇ l or more can be obtained from 100 ⁇ l blood.
- the device according to the invention is therefore particularly suitable in the field of modern Analysis to be used because even with the removal of small sample volumes a rapid plasma separation, as well as the output of the plasma advantageously on a test strip.
- the volume of blood given is preferably 30 to 150 ul, can be sufficient by means of the device according to the invention Plasma quantities are obtained, which are prescribed for commercially available test elements so that an analyte concentration is independent of the sample volume can be determined. It is consequently by means of the device according to the invention possible to obtain sufficiently large amounts of plasma despite low blood volumes, the requirements of commercial analysis methods, especially with test elements to suffice.
- the device according to the invention also allows a particularly simple and cost-effective production of the system because z. B. no microstructures (microchannels) must be integrated into the device during the manufacturing process.
- the separation of the plasma takes place by means of a separating element, which is advantageously unique Use is designed. A blockage of the microporous structures with repeated Use and contamination can thus be avoided.
- the plasma separation only accelerates to the extent that reliable separation of the plasma from the remaining blood components is guaranteed.
- here are processes that, for. B. shear forces to avoid conditions that cause hemolysis during plasma separation would.
- the invention consequently enables an accelerated process of Plasma separation without contamination of the plasma with the rest Blood components must be accepted.
- the invention is in particular the object of pure plasma on test elements suitable, which - as described - a complexing agent contain and due to the complexing agent a plasma separation within of the test element itself cannot be realized.
- test elements that do not Contain complexing agents.
- the plasma is also commercially available here using a Separation layer in the test element itself can be separated and the user consequently when using these test elements not on a separate plasma separation the system according to the invention allows e.g. here a simplified one Structure of the test elements.
- the test elements therefore only have to be placed over a reagent layer and no longer have a separation layer or separation fleece. This results in u. a. a reduction in the production steps leading to cost reduction of the test elements.
- test element Based on the test elements described in the prior art with a separation layer or separation fleece is a preferred embodiment of an inventive Separating element built in a first approximation according to an analog principle.
- a separation layer z. B. referred to the document DE 3130749.
- the document describes a Test element in which the plasma is first separated from the blood, so that exclusively Plasma is passed to a reagent layer. With the help of the reagent an analyte is now determined in plasma.
- the test element a flat separation layer arranged on the base strip, onto which the blood sample is given to one end.
- the separation layer consists of glass fiber material, restrains the blood cells near the task site.
- the blood plasma on the other hand spreads in the shift, so that in the of the task position distant area of the separation layer a "plasma lake" is available.
- a plasma lake usually there is a reagent layer above or below the plasma lake, which can then be used to determine the analyte in the plasma.
- a test carrier are appropriate evaluation devices, as in State of the art are used.
- a device contains a separating element that has the structure of a reproduces such test element in a simplified manner includes such a separating element
- a separation layer which also below is referred to as a separating fleece and, in a second area, a transport fleece, in which the plasma collects in a distant area from the separation layer.
- a preferred embodiment of the separating element consequently has a test carrier analog, strip-like structure without a reagent layer.
- the Separating element preferably includes a filter in its separating fleece, which, for. B. from Glass fiber material exists, so that an essentially complete separation of the Plasma is guaranteed by blood.
- Other commercially available nonwovens are e.g. B.
- the filtering process is essentially according to the invention not supported by pressure, causing destruction of blood cells in the first Area of the separating element is avoided. Still acts to support the Filtering process z. B. a negative pressure on the first region of the separating element, so care must be taken to ensure that pressure is only exerted to the extent that this causes no hemolysis is effected.
- the plasma is then released by acting on the second one Area of the separating element without influencing the first area of the separating element becomes. Contamination of the plasma by the plasma release process step is thus prevented according to the invention.
- the process step of plasma release according to the invention takes place independently of the plasma separation, so that from the Process step of plasma separation no restrictions for the Plasma release results.
- Another example of plasma release is that Elute the separated plasma. Via an outlet of the device then the released plasma is dispensed in doses.
- a separation of the second area of the separating element from the first area can e.g. B. be realized by a bracket that with the second area of Separating element is connected. If the user exerts a force (pulling, pushing, Turning etc.) exerted on this bracket, this force is directly or indirectly on the transferred second region of the separating element and thereby leads to the separation of the second area.
- a force pulseling, pushing, Turning etc.
- the separating element is separated and the subsequent release of the plasma from the second area in two successive steps, by actuating one and the same release unit done on the device.
- a trigger unit is then with the bracket connected to the device in such a way that when the Tripping unit is first cut through and a further actuation of the trigger unit leads to plasma release.
- Trip units as described, are advantageously realized in the form of a release button that in a first step z. B. first causes rotation of a bracket with the second area of the separating element is connected, so that a rotation of this separating element area results. During the rotation of the attached in the holder second area, the first part of the separating element remains stationary in the device.
- the forces caused by the rotary movement lead to the division of the Separating element.
- a cutting element in the device is positioned so that the second area of the separating element during the rotary movement is pressed against the cutting element.
- a division of the separating element is thus facilitated and can be carried out precisely.
- cutting the separating element can also by Tear off the first area from the second area. Then will the plasma is released by means of the output unit.
- the separating element is as Disposable items designed so that an irreversible severing of the element is not is disadvantageous, it is also conceivable for the holder to also be fixed to the separating element offer related one-off items.
- the user that would be Handling of the device when reinserting a new separating element is greatly simplified, handling of small device components, especially in the case of older people Creates difficulties.
- the invention furthermore relates to a method for plasma separation and Output.
- the method involves applying blood to a first area of a Separating element, which includes a first and a second region.
- the Plasma is separated from other blood components, the Plasma is forwarded to the second area of the separating element and the remaining Blood components essentially in the first area of the separating element be held back.
- the second area of the separating element is then in processed in such a way that the plasma from the second region of the separating element is released. It is important to ensure that the first area is not processed of the separating element, which is contaminated, for example, by hemolysis of the plasma with the previously separated blood components would.
- the released plasma is output via an outlet of the device.
- the process for plasma separation and release takes place by means of a device as described.
- FIG. 1 shows an example of the structure of a separating element (1).
- the separating element (1) contains a transport fleece (2) which, for. B. consists of glass fibers.
- a separating fleece (3) consisting of a filter medium is attached to the transport fleece (2).
- Transport and separation fleece differ essentially in terms of their different densities.
- B. a density of 77 g / cm 2 for a separating fleece and 53 g / cm 2 for a transport fleece (Whatman fleece).
- the lower density of the transport fleece enables the sample to be transported quickly along the fleece, while the higher density of the separating fleece ensures reliable separation of the plasma from blood.
- a drop of blood (5) is applied, the blood enters the separating fleece (3).
- the release unit therefore does not act on the transition zone of the transport fleece when the plasma is released, in order to avoid contamination of the rest of the plasma with the contaminants present here.
- the recess of the transition zone z. B. realized by a separation of the second area of the test element from the first area beyond this transition zone, so that the extraction of pure plasma is guaranteed.
- FIG 2 a) to c) shows an example of a method for plasma separation with an inventive Device (10).
- the device contains a hollow body (14), which has an outlet (13).
- the separating element is inside the hollow body (1) arranged in such a way that the separating fleece (3) protrudes from the hollow body (14) and is easily accessible to the user.
- the transport fleece (2) is inside of the hollow body (14).
- the device further includes a stamp (12) which is movably mounted within the device (14).
- the radius of the stamp (12) substantially equal to the inner radius of the hollow body (14), so that the Stamp (12) can be moved within the device by means of a button (11) can.
- Figure 2 b) shows a blood application (5) on a separating fleece (3) of a separating element (1).
- the plasma is passed along the separation fleece, while the remaining blood components are retained in the separation fleece. A complete plasma separation took place after approx. 2 to 10 seconds.
- the separated plasma is now passed on to the transport fleece (2).
- the button (11) is first the stamp (12) against the transport fleece (2) pressed so that this area of the separating element within the hollow body (14) is carried away by the stamp. Since the separating fleece (3) is positioned in the hollow body is, the transport fleece is separated from the separating fleece, one Separation takes place beyond the transition zone (6) shown in FIG. 1.
- the stamp (12) presses the plasma out of the Transport fleece (2) and releases them. Above the outlet (13) of the device plasma is then released (7).
- the plasma can, for. B. on a test element (17) can be applied to determine the HDL concentration.
- FIG. 3 shows different views of a further embodiment of the device (a - c).
- the device includes a rotatably mounted holder (21) in which a separating element (1) inside a channel (23) is positioned.
- the separating element (1) is in the holder positioned that the separating fleece (3) outside the holder and the device protrudes, so that - as it is shown in the side views - for the User for blood supply is easily accessible.
- the device also has a stamp (12) which is connected to the button (11). Furthermore, by means of the knob (11) a rotary element (22) are operated. First of all there is a blood test on the separating fleece (3) of the separating element (1), as in Figure 3 a) the side view is shown.
- the rotary element (22) is actuated.
- the holder (21) rotated approx. 90 °.
- the separating fleece (3) is separated from the transport fleece (2), the transition zone (6) of the transport fleece (2) remaining on the separating fleece (3).
- the stamp (12) that is initially located within the channel (23 a), transferred into the channel area (23 b).
- the transport fleece to be pressed against an outlet (13). located sieve (24).
- the sieve (24) preferably has a small thickness of 20 to 300 ⁇ m to avoid excessive dead volume. Via the outlet (13) the plasma is output.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ecology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
- Figur 1:
- Aufbau eines Trennelementes
- Figur 2:
- Vorrichtung zur Separierung von Plasma
- Figur 3:
- Vorrichtung zur Separierung von Plasma mit einer drehbar gelagerten Halterung
Claims (21)
- Vorrichtung zur Separierung und Ausgabe von Plasma beinhaltendein Trennelement, das einen ersten und einen zweiten Bereich beinhaltet, unddas Trennelement in der Vorrichtung in der Weise angeordnet ist, dass der erste Bereich für den Benutzer zur Blutaufgabe zugänglich ist,eine Ausgabeeinheit, die nach der Plasmaseparation im wesentlichen auf den zweiten Bereich des Trennelementes wirkt, ohne dass eine Einwirkung der Ausgabeeinheit auf den ersten Bereich des Trennelementes erfolgt, sodass das separierte Plasma aus dem zweiten Bereich des Trennelementes freigesetzt wird und über einen Auslass der Vorrichtung abgegeben wird.
- Vorrichtung gemäß Anspruch 1,
bei dem das Trennelement ein Einmalartikel ist. - Vorrichtung gemäß Anspruch 1,
bei dem der erste Bereich des Trennelementes lateral neben dem zweiten Bereich des Trennelementes in der Weise innerhalb der Vorrichtung angeordnet ist, dass die Ausgabeeinheit im wesentlichen senkrecht zu der Ebene, in der sich das Trennelement befindet, auf den zweiten Bereich des Trennelementes wirkt. - Vorrichtung gemäß Anspruch 1,
bei der der zweite Bereich des Trennelementes in einer innerhalb der Vorrichtung beweglichen Halterung befestigt ist. - Vorrichtung gemäß Anspruch 4,
bei der eine Drehung der Halterung um vorzugsweise 90° möglich ist, wodurch eine Abtrennung des zweiten Bereichs des Trennelementes vom ersten Bereich bewirkt wird. - Vorrichtung gemäß Anspruch 1,
bei der der zweiten Bereich des Trennelementes vom ersten Bereich des Trennelementes abgetrennt wird und das Abtrennen sowie das Freisetzen von Plasma aus dem zweiten Bereich in zwei hintereinander folgenden Schritten durch Betätigen einer Auslöseeinheit an der Vorrichtung erfolgt. - Vorrichtung gemäß Anspruch 1,
bei der der erste Bereich des Trennelementes ein Trennvlies und der zweite Bereich des Trennelementes ein Transportvlies beinhaltet. - Vorrichtung gemäß Anspruch 1,
bei der der zweite Bereich des Trennelementes mittels eines Stempels ausgepresst wird. - Vorrichtung gemäß Anspruch 1,
bei der das Trennelement streifenförmig ist. - System zum Nachweis von Analyten im Blut beinhaltend:ein Trennelement, das in einer Vorrichtung in der Weise angeordnet ist, dass ein erster Bereich des Trennelementes für den Benutzer zur Blutaufgabe zugänglich ist,
wobei bei Blutaufgabe auf den ersten Bereich des Trennelementes Plasma in einen zweiten Bereich des Trennelementes geleitet wird und die restlichen Blutbestandteile im wesentlichen vollständig im ersten Bereich des Trennelementes zurückgehalten werden, undeine Ausgabeeinheit, die nach der Plasmaseparation im wesentlichen auf den zweiten Bereich des Trennelementes wirkt, ohne dass eine Einwirkung der Ausgabeeinheit auf den ersten Bereich des Trennelementes erfolgt, sodass das separierte Plasma aus dem zweiten Bereich des Trennelementes freigesetzt wird und über einen Auslass der Vorrichtung abgegeben wird, sowieein Testelement, das bei Aufgabe des separierten Plasmas einen Nachweis eines Analyten im Plasma ermöglicht. - System gemäß Anspruch 10,
bei dem der Aufbau des Testelementes in der Weise vereinfacht ist, dass keine Plasmaseparierung durch das Testelement selbst erfolgt. - Verfahren zur Plasmaseparierung und -ausgabe beinhaltendAufgabe von Blut auf einen ersten Bereich eines Trennelements,Separierung eines Plasmas von anderen Blutbestandteilen mittels des Trennelementes, wobei die Blutbestandteile im wesentlichen im ersten Bereich des Trennelementes zurückgehalten werden, und das Plasma in einen zweiten Bereich des Trennelementes weitergeleitet wird,anschließend Bearbeitung des zweiten Bereiches des Trennelementes, ohne dass ein Einwirken auf den ersten Bereich des Trennelementes erfolgt, sodass das Plasma aus dem zweiten Bereich des Trennelementes freigesetzt wird, undAusgabe von freigesetztem Plasma über einen Auslass.
- Verfahren gemäß Anspruch 12,
bei dem der zweite Bereich des Trennelementes vom ersten Bereich des Trennelementes abgetrennt wird. - Verfahren gemäß Anspruch 12,
bei dem aus dem zweiten Bereich des Trennelementes das separierte Plasma eluiert wird. - Verfahren gemäß Anspruch 12,
bei dem aus dem zweiten Bereich des Trennelementes das separierte Plasma mittels Druck freigesetzt wird. - Verfahren gemäß Anspruch 12,
bei dem die Plasmaseparation aufgrund eines Filterungsprozess erfolgt. - Verfahren gemäß Anspruch 16,
bei dem durch einen Unterdruck der Filterungsprozess unterstützt wird. - Verfahren gemäß Anspruch 12,
das zur Bestimmung von Lipoproteinen mit hoher Dichte verwendet wird. - Verfahren gemäß Anspruch 12,
bei dem vorzugsweise das aufgegebene Blutvolumen 30 µl bis 150 µl beträgt. - Verfahren gemäß Anspruch 12,
bei dem eine Plasmaabtrennung, -freisetzung und -ausgabe mit einer Vorrichtung gemäß einer der Ansprüche 1 - 9 erfolgt. - Vorrichtung gemäß Anspruch 1,
die für ein Verfahren gemäß einer der Ansprüche 12 - 19 geeignet ist.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10252223A DE10252223A1 (de) | 2002-11-11 | 2002-11-11 | Vorrichtung zur Separierung und Ausgabe von Plasma |
DE10252223 | 2002-11-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1421993A1 true EP1421993A1 (de) | 2004-05-26 |
EP1421993B1 EP1421993B1 (de) | 2007-02-21 |
Family
ID=32185422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03025228A Expired - Lifetime EP1421993B1 (de) | 2002-11-11 | 2003-11-05 | Vorrichtung zur Separierung und Ausgabe von Plasma |
Country Status (7)
Country | Link |
---|---|
US (2) | US7404931B2 (de) |
EP (1) | EP1421993B1 (de) |
JP (1) | JP2004177404A (de) |
AT (1) | ATE354439T1 (de) |
CA (1) | CA2448433C (de) |
DE (2) | DE10252223A1 (de) |
ES (1) | ES2280669T3 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009109997A1 (en) * | 2008-03-07 | 2009-09-11 | Advanced Microdevices Pvt Ltd | Method and device for particle removal and droplet preparation for qualitative and quantitative bioanalysis |
WO2012062651A1 (de) | 2010-11-10 | 2012-05-18 | Boehringer Ingelheim Microparts Gmbh | Vorrichtung zur filtration von blut |
WO2012127050A2 (de) | 2011-03-24 | 2012-09-27 | Boehringer Ingelheim Microparts Gmbh | Vorrichtung und verfahren zur filtration von blut |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1478992A4 (de) * | 2002-02-07 | 2007-03-21 | Univ Utah Res Found | Verfahren zum erzeugen und verwenden eines behandlungsprotokolls |
US8075468B2 (en) | 2008-02-27 | 2011-12-13 | Fenwal, Inc. | Systems and methods for mid-processing calculation of blood composition |
US8685258B2 (en) | 2008-02-27 | 2014-04-01 | Fenwal, Inc. | Systems and methods for conveying multiple blood components to a recipient |
US11360076B2 (en) * | 2012-03-30 | 2022-06-14 | Weavr Health Corp. | Methods and systems to collect a biological sample |
US11358138B2 (en) * | 2013-07-19 | 2022-06-14 | Boston Microfluidics Inc. | Fluid sample collection device |
DE102013012678A1 (de) | 2013-07-31 | 2015-02-05 | Mann + Hummel Gmbh | Flachfiltermedien zur abtrennung von plasma oder serum von vollblut |
WO2016073415A2 (en) | 2014-11-04 | 2016-05-12 | Wainamics, Inc. | Microscale plasma separator |
WO2018175169A1 (en) | 2017-03-20 | 2018-09-27 | Wainamics, Inc. | Small volume self-metered blood separation device |
CA3080117A1 (en) | 2017-10-27 | 2019-05-02 | Juno Diagnostics, Inc. | Devices, systems and methods for ultra-low volume liquid biopsy |
JP2021501340A (ja) | 2017-10-27 | 2021-01-14 | ボストン・マイクロフルイディクス・インコーポレーテッドBoston Microfluidics,Inc. | 液体試料採取装置 |
US11484877B2 (en) | 2018-05-29 | 2022-11-01 | Weavr Health Corp. | Blood metering device with desiccant and support for storage media and inlay with flange |
WO2020086397A1 (en) | 2018-10-23 | 2020-04-30 | Boston Microfluidics, Inc. | Funnel with extension tube to augment blood collection device |
US20220395620A1 (en) * | 2019-10-18 | 2022-12-15 | Tasso, Inc. | Plasma separation devices and related methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4477575A (en) * | 1980-08-05 | 1984-10-16 | Boehringer Mannheim Gmbh | Process and composition for separating plasma or serum from whole blood |
US5130231A (en) * | 1985-10-18 | 1992-07-14 | Chem-Elec, Inc. | Blood plasma test device including a semipermeable membrane made of an expanded hydrophobic material that has been treated with a surfactant |
DE19629656A1 (de) * | 1996-07-23 | 1998-01-29 | Boehringer Mannheim Gmbh | Diagnostischer Testträger mit mehrschichtigem Testfeld und Verfahren zur Bestimmung von Analyt mit dessen Hilfe |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3596652A (en) * | 1968-10-14 | 1971-08-03 | Bio Science Labor | Fluid separatory device |
US3794469A (en) * | 1970-03-02 | 1974-02-26 | Becton Dickinson Co | Blood test system |
US3791933A (en) * | 1971-02-25 | 1974-02-12 | Geomet | Rapid methods for assay of enzyme substrates and metabolites |
US3897340A (en) * | 1974-02-27 | 1975-07-29 | Becton Dickinson Co | Serum/plasma separator assembly with interface-seeking piston having coarse and fine band filters |
US4226713A (en) * | 1978-04-24 | 1980-10-07 | Goldberg Jack M | Diagnostic agents |
DE3130749C2 (de) | 1981-08-04 | 1984-06-07 | Boehringer Mannheim Gmbh, 6800 Mannheim | Schnelldiagnostikum und Verfahren zu seiner Verwendung, insbesondere für quantitative Bestimmungen |
US4883764A (en) * | 1987-07-20 | 1989-11-28 | Kloepfer Mary A | Blood test strip |
JPH05188053A (ja) * | 1992-01-10 | 1993-07-27 | Sanwa Kagaku Kenkyusho Co Ltd | 血液から血清又は血漿成分を分離する器具 |
CA2178523C (en) | 1995-06-09 | 2001-08-28 | Tomohiro Kitagawa | Plasma separation filter, plasma separation method using the same and plasma separation apparatus |
DE69619400T2 (de) * | 1995-06-16 | 2002-09-26 | Univ Washington Seattle | Flacher mikrogefertigter querstromfilter für flüssigkeiten |
JPH09196911A (ja) | 1996-01-19 | 1997-07-31 | Fuji Photo Film Co Ltd | 血液濾過ユニット |
US6869405B2 (en) * | 2001-03-30 | 2005-03-22 | Becton, Dickinson And Company | Blunt cannula and filter assembly and method of use with point-of-care testing cartridge |
-
2002
- 2002-11-11 DE DE10252223A patent/DE10252223A1/de not_active Withdrawn
-
2003
- 2003-11-05 DE DE50306571T patent/DE50306571D1/de not_active Expired - Lifetime
- 2003-11-05 ES ES03025228T patent/ES2280669T3/es not_active Expired - Lifetime
- 2003-11-05 EP EP03025228A patent/EP1421993B1/de not_active Expired - Lifetime
- 2003-11-05 AT AT03025228T patent/ATE354439T1/de active
- 2003-11-06 CA CA002448433A patent/CA2448433C/en not_active Expired - Lifetime
- 2003-11-07 JP JP2003378957A patent/JP2004177404A/ja active Pending
- 2003-11-10 US US10/705,713 patent/US7404931B2/en active Active
-
2008
- 2008-06-18 US US12/141,176 patent/US7993607B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4477575A (en) * | 1980-08-05 | 1984-10-16 | Boehringer Mannheim Gmbh | Process and composition for separating plasma or serum from whole blood |
US4477575B1 (de) * | 1980-08-05 | 1992-04-21 | Boehringer Mannheim Gmbh | |
US5130231A (en) * | 1985-10-18 | 1992-07-14 | Chem-Elec, Inc. | Blood plasma test device including a semipermeable membrane made of an expanded hydrophobic material that has been treated with a surfactant |
DE19629656A1 (de) * | 1996-07-23 | 1998-01-29 | Boehringer Mannheim Gmbh | Diagnostischer Testträger mit mehrschichtigem Testfeld und Verfahren zur Bestimmung von Analyt mit dessen Hilfe |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009109997A1 (en) * | 2008-03-07 | 2009-09-11 | Advanced Microdevices Pvt Ltd | Method and device for particle removal and droplet preparation for qualitative and quantitative bioanalysis |
US8470259B2 (en) | 2008-03-07 | 2013-06-25 | Advanced Microdevices Pvt Ltd | Method and device for particle removal and droplet preparation for qualitative and quantitative bioanalysis |
WO2012062651A1 (de) | 2010-11-10 | 2012-05-18 | Boehringer Ingelheim Microparts Gmbh | Vorrichtung zur filtration von blut |
WO2012127050A2 (de) | 2011-03-24 | 2012-09-27 | Boehringer Ingelheim Microparts Gmbh | Vorrichtung und verfahren zur filtration von blut |
Also Published As
Publication number | Publication date |
---|---|
DE10252223A1 (de) | 2004-05-27 |
JP2004177404A (ja) | 2004-06-24 |
US7404931B2 (en) | 2008-07-29 |
CA2448433C (en) | 2008-01-29 |
CA2448433A1 (en) | 2004-05-11 |
US20090155762A1 (en) | 2009-06-18 |
DE50306571D1 (de) | 2007-04-05 |
ES2280669T3 (es) | 2007-09-16 |
ATE354439T1 (de) | 2007-03-15 |
US7993607B2 (en) | 2011-08-09 |
EP1421993B1 (de) | 2007-02-21 |
US20040222168A1 (en) | 2004-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1421993B1 (de) | Vorrichtung zur Separierung und Ausgabe von Plasma | |
EP0949002B1 (de) | Verfahren zur Herstellung von analytischen Hilfsmitteln | |
DE60124514T2 (de) | Verfahren zur Verhinderung der ungenügenden Probenahme einer Kapillar- oder Dochtwirkungsfüllvorrichtung | |
DE68916458T2 (de) | Verfahren und Gerät zur Trennung einer Körperflüssigkeit von Teilchen in dieser Flüssigkeit und Testsatz für diese Trennung und Analyse der Körperflüssigkeit. | |
DE69716543T2 (de) | Vorrichtung zum Entnehmen und Analysieren von flüssigen Proben, wie Blutproben | |
DE69737332T2 (de) | Vorrichtung und Verfahren zur Analyse einer Probe | |
DE60221080T2 (de) | Vorrichtungen zur Bestimmung der Analytkonzentration und ihre Herstellung und Verwendung | |
EP0634215A1 (de) | Vorrichtung zur gleichzeitigen Bestimmung von Analyten | |
DE69022999T2 (de) | Wegwerfblutbehandlungskassette zum messen der haemostasen. | |
DE2907787C2 (de) | ||
DE10305050A1 (de) | Analytisches Testelement und Verfahren für Blutuntersuchungen | |
DE60107538T2 (de) | Vorrichtung zum trennen und nachweis von bewegungsfähigen spermatozoen | |
EP1315553B1 (de) | Vorrichtung und verfahren zur separation von ungelösten bestandteilen aus biologischen flüssigkeiten | |
EP1522343B1 (de) | Analytisches Testelement umfassend ein hydrophiles Netzwerk zur Bildung eines Kapillarkanals, dessen Verwendung und Verfahren zur Bestimmung eines Analyten in einer Flüssigkeit | |
EP2902099B1 (de) | Probenvorbereitungs- und testsystem | |
EP1507589B1 (de) | Vorrichtung zur probennahme von flüssigen proben | |
EP1541986A1 (de) | Probennahmeeinrichtung und System zur Untersuchung von Probenflüssigkeit | |
DE102005061561A1 (de) | Laser-Mikrodissektionsverfahren, Steuersystem für eine Laser-Mikrodissektionsvorrichtung und Trägervorrichtung | |
DE10011235A1 (de) | Vorrichtung zur manuellen Probenaufnahme | |
DE3217591A1 (de) | Analysengeraet, insbesondere zur untersuchung von fluessigkeitsproben | |
DE102013000901B4 (de) | Vorrichtung zur Aufnahme und Abgabe von Speichel | |
EP1434637A2 (de) | Verfahren und trennmodul zum abtrennen von partikeln aus einer dispersion, insbesondere von blutkörperchen aus blut | |
EP3973288B1 (de) | Mikrofluidisches analysesystem zur analyse von blutproben | |
WO1997018895A2 (de) | Einwegauftragsvorrichtung sowie kit | |
DE1598877B2 (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
17P | Request for examination filed |
Effective date: 20041126 |
|
AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20050422 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ROCHE DIAGNOSTICS GMBH Owner name: F.HOFFMANN-LA ROCHE AG |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 50306571 Country of ref document: DE Date of ref document: 20070405 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070521 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20070522 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20070501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070723 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2280669 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 |
|
26N | No opposition filed |
Effective date: 20071122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070522 |
|
BERE | Be: lapsed |
Owner name: F.HOFFMANN-LA ROCHE A.G. Effective date: 20071130 Owner name: ROCHE DIAGNOSTICS G.M.B.H. Effective date: 20071130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070822 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070221 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20141105 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20141027 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20141119 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 354439 Country of ref document: AT Kind code of ref document: T Effective date: 20151105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151105 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20161228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151106 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20221020 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20221012 Year of fee payment: 20 Ref country code: DE Payment date: 20221012 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20221201 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 50306571 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20231104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20231104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20231104 |